Cite
HARVARD Citation
Lacour, J. et al. (2017). Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. Journal of the European Academy of Dermatology and Venereology. pp. 847-856. [Online].